Sure ....still unclear if ps exposure is the holy grail many here, and few outside of here, believe. Do you think researchers, pharmas, bio analysts, bio media and others do not know about ps exposure or do they not believe? Hard to imagine they do not know so .... It clearly does not work in all cases, first line trial was cancelled do to no benefit over soc, remember? Without a partner, it will be a long slow haul to see if PIII confirms efficacy with dox in nsclc.
News 
Market Data 
Discover 
